Evidence map›Paper›PMID 42965173›Full record

ReviewKidney medicine2026

Clinical Application of Hemadsorption in Maintenance Hemodialysis Patients: An Adapted English Republication of the Chinese HA-MHD Consensus.

Xiaohua Sheng, Wei Lu, Zhiyong Guo, Shan Mou, Zhaohui Ni, Xiaoqiang Ding, Yueyi Deng, Guisen Li, Jun Liu, Pengli Luo and 14 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Kidney medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Xiaohua ShengDepartment of Nephrology, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Wei LuDepartment of Nephrology, Rheumatology and Immunology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhiyong GuoDepartment of Nephrology, First Affiliated Hospital of Naval Medical University, Shanghai, China.
Shan MouDepartment of Nephrology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhaohui NiDepartment of Nephrology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xiaoqiang DingDepartment of Nephrology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yueyi DengDepartment of Nephrology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Guisen LiDepartment of Nephrology, Sichuan Provincial People's Hospital, Chengdu, China.
Jun LiuDepartment of Nephrology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Pengli LuoDepartment of Nephrology, Affiliated Hospital of Qinghai University, Xining, China.
Shiren SunDepartment of Nephrology, Xijing Hospital, Air Force Medical University, Xi'an, China.
Huiming WangDepartment of Nephrology, Renmin Hospital of Wuhan University, Wuhan, China.
Jiali WeiDepartment of Nephrology, Hainan General Hospital, Haikou, China.
Xudong XuDepartment of Nephrology, Minhang Hospital, Fudan University, Shanghai, China.
Xiangdong YangDepartment of Nephrology, Qilu Hospital, Shandong University, Jinan, China.
Zhenhua YangDepartment of Nephrology, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Wen ZhangDepartment of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jianrong ZhaoDepartment of Nephrology, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
Xiaoling ZhouDepartment of Nephrology, General Hospital of Ningxia Medical University, Yinchuan, China.
Xiaoshuang ZhouDepartment of Nephrology, Shanxi Provincial People's Hospital, Taiyuan, China.
Zhu ZhouDepartment of Nephrology, First Affiliated Hospital of Kunming Medical University, Kunming, China.
Gengru JiangDepartment of Nephrology, Rheumatology and Immunology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Niansong WangDepartment of Nephrology, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Nephrology Branch of the Shanghai Medical Association and the 2025 HA–MHD Consensus Working Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The accumulation of protein-bound uremic toxins and middle- to large-molecular-weight toxins in patients receiving maintenance hemodialysis (MHD) results in long-term complications. Hemadsorption (HA) can efficiently remove these uremic toxins and reduce the risk of long-term complications in MHD patients. The Chinese HA-MHD Consensus Working Group has revised and updated the 2021 Shanghai Expert Consensus on the Clinical Application of Haemoadsorption in Maintenance Haemodialysis Patients to further standardize clinical application of HA and reflect the latest evidence. Based on an extensive literature search, the Grading of Recommendations Assessment, Development and Evaluation framework, and the modified Delphi method, the working group formulated 27 evidence-based recommendations regarding patient populations, session frequency, treatment modalities, precautions, and adverse reactions. This consensus systematically delineates the clinical thresholds and rationales for utilizing HA across three core dimensions: routine treatment regimens, intensive treatment regimens, and long-term complication risk management to provide comprehensive guidance. Furthermore, the consensus provides detailed guidance on individualized operational parameters to maximize both safety and treatment efficacy. This consensus aims to provide the latest guiding opinions for the rational and standardized application of HA therapy in patients receiving MHD.

Indexed as

expert consensushemadsorptionhemoperfusionmaintenance hemodialysisprotein-bound uremic toxins

Identifiers

PMID42965173
PMCPMC13722071

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.